leisure time -WSS

leisure time

author：explore 2025-09-28 00:52:55 - browse：42

Warning sign illustration made of 0s and 1s. -- first opinion coverage from sTAT — Adobe

Big businesses poised to profit from the advance of artificial intelligence in health care are pushing back against newly proposed federal rules meant to increase oversight and fairness of AI tools used to help make decisions about patient care.

The opposition, which includes Google and Amazon as well as large health care providers, insurers, and medical software vendors, is focused on an attempt to put tighter guardrails around the use of AI by the Office of the National Coordinator for Health Information Technology.

The agency wants to require developers of electronic health records and other health software to provide users with details about the training and testing of predictive models that draw data from their systems, or are hosted within them. It also wants developers to assess and publicly disclose potential risks and create a way for clinicians and other users to report problems.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Devoted Health’s losses in Medicare Advantage persist

WSS

Readout Newsletter: Amgen, Regeneron, BGI Group and more

The drug industry has found itself all alone in Washington

Top private equity targets in 2023: cardiology, clinical trials, lasers

Change Healthcare payments predicted restored March 15

AI gets buy

Adopting new red light myopia treatments may be short

leisure time

leisure time

explore

How one medical school became remarkably diverse

A single Democrat is willing to weaken Medicare negotiation power

Walensky prepares to leave CDC — and Congress — behind

340B reform proposal comes out of Senate working group

State Dept. review finds Biden bears some blame for Afghanistan failures

Bernie brings in new pharma CEOs to talk drug prices

State Dept. review finds Biden bears some blame for Afghanistan failures

A protest over insulin prices is seen as a fight for life

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Padmanee Sharma of MD Anderson at center of lawsuit over credit

focus

Novo Nordisk obesity pill bests Wegovy in early trial

The drug industry has found itself all alone in Washington

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

How to bring more disabled researchers into academia

Updated Covid vaccine has 54% effectiveness, new study suggests

leisure time

focus

hotspot

explore